दवाओं की अंतःक्रिया
Factor viii + Marstacimab
गंभीरता: गंभीर
Factor viii and Marstacimab: major interaction.
अंतिम अपडेट
केवल स्वास्थ्य पेशेवरों के लिए — मात्र संदर्भ हेतु। यह पृष्ठ संक्षिप्त सारांश है, चिकित्सकीय सलाह नहीं है और आधिकारिक लेबल या नैदानिक निर्णय का विकल्प नहीं है। दवा लिखने या देने से पहले हमेशा जाँच करें।
इस पृष्ठ की नैदानिक सामग्री केवल अंग्रेज़ी में उपलब्ध है।
सारांश
Marstacimab inhibits tissue factor pathway inhibitor and raises hemostatic potential, and adding factor VIII concentrates may further increase the risk of thromboembolic events. Factor VIII used for prophylaxis should be discontinued before starting marstacimab.
इस इंटरैक्शन का सरल भाषा में अर्थ
Factor viii and Marstacimab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Factor viii belongs to Cardiovascular; Marstacimab belongs to Cardiovascular.
ऐसा क्यों होता है
Additive procoagulant pharmacodynamic effects of TFPI inhibition and exogenous factor VIII.
क्या करें
Stop factor VIII prophylaxis before starting marstacimab, and use the lowest effective factor VIII dose only for breakthrough bleeds. Monitor for signs of thrombosis.
फार्मासिस्ट से क्या पूछें
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ सदस्यों के लिए
पूरा पेज खोलें
Factor viii और Marstacimab की पूरी प्रबंधन सलाह, अतिरिक्त नोट्स, साक्ष्य का विवरण और पूरे पर्चे का इंटरैक्शन चेकर खोलने के लिए खाता बनाएँ और Pro+ ट्रायल शुरू करें।
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
वेब पर Pro+ को 7 दिन मुफ़्त आज़माएँ। कार्ड की ज़रूरत नहीं।
Factor viii के अन्य इंटरैक्शन
- Concizumab + Factor viii गंभीर
अक्सर पूछे जाने वाले प्रश्न
Can I take Factor viii with Marstacimab?
MediHelp rates the interaction as major. Factor viii and Marstacimab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Marstacimab inhibits tissue factor pathway inhibitor and raises hemostatic potential, and adding factor VIII concentrates may further increase the risk of thromboembolic events. Factor VIII used for prophylaxis should be discontinued before starting marstacimab.
How serious is the interaction between Factor viii and Marstacimab?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Stop factor VIII prophylaxis before starting marstacimab, and use the lowest effective factor VIII dose only for breakthrough bleeds. Monitor for signs of thrombosis.
What other medicines interact with Factor viii?
MediHelp also lists interactions of Factor viii with, for example, Concizumab. The full list is on the Factor viii page.
MediHelp ऐप में पूर्ण मोनोग्राफ़, खुराक और इंटरैक्शन चेकर
MediHelp ऐप में पूरा संदर्भ खोलें, कई दवाओं की अंतःक्रियाएँ जाँचें और खुराक टूल इस्तेमाल करें।
